Dr. Stephan Fleck is new Managing Director of the pharmaceutical contract manufacturer Rottendorf Pharma in Ennigerloh/Germany. He follows Peter J. Verheyen who has left the company after 12 years. Verheyen, however, will be responsible for the subsidiary Rottendorf SAS Valenciennes/France until the end of 2009.
Fleck obtained the masters degree of science in Physics and started his career at Bayer AG Leverkusen/Germany where he held several positions, among them finally the position of Senior Project Engineer. Afterwards he went to Bayer Diagnostics/United States for five years and became Head of Manufacturing Technology. On his return to Leverkusen, he was first employed in the Global Strategic Planning at Bayer Healthcare and then took up the position as Plant Manager Solids Packaging Pharmaceuticals. Finally, he was appointed as Vice President Technical Operations at General Electric Healthcare Life Science in London.
The Rottendorf Group currently has 780 employees and noted a turnover of around 97 million Euro in 2008. As one of the leading pharmaceutical service providers for the development, production and packaging of solid dosage forms, Rottendorf works with several of the biggest Big Pharma companies. The future company strategy focuses on contract development of solid forms as well as on operational excellence.
Fleck obtained the masters degree of science in Physics and started his career at Bayer AG Leverkusen/Germany where he held several positions, among them finally the position of Senior Project Engineer. Afterwards he went to Bayer Diagnostics/United States for five years and became Head of Manufacturing Technology. On his return to Leverkusen, he was first employed in the Global Strategic Planning at Bayer Healthcare and then took up the position as Plant Manager Solids Packaging Pharmaceuticals. Finally, he was appointed as Vice President Technical Operations at General Electric Healthcare Life Science in London.
The Rottendorf Group currently has 780 employees and noted a turnover of around 97 million Euro in 2008. As one of the leading pharmaceutical service providers for the development, production and packaging of solid dosage forms, Rottendorf works with several of the biggest Big Pharma companies. The future company strategy focuses on contract development of solid forms as well as on operational excellence.
